EVER Pharma Spain

Fulvestrant EVER Pharma

Oncology
1 Strength – 250 mg/5 ml

The first Fulvestrant in Europe approved for storage at room temperature.

Fulvestrant EVER Pharma is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

  • Not previously treated with endocrine therapy
  • Or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.

Fulvestrant EVER is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

Learn more: www.evervalinject.com